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Edited by Peter Tontonoz and Laszlo NagyAbstract Farnesoid X receptor (FXR), a member of the nuclear
receptor superfamily, has been shown to be important in control-
ling numerous metabolic pathways; these include roles in main-
taining bile acid, lipid and glucose homeostasis, in preventing
intestinal bacterial infection and gallstone formation and in mod-
ulating liver regeneration and tumorigenesis. The accumulating
data suggest that FXR may be a pharmaceutical target for the
treatment of certain metabolic diseases.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Farnesoid X receptor (FXRa, NR1H4), a member of the
nuclear receptor (NR) superfamily, was originally cloned in
1995 [1,2]. The conservation of FXRa amino acid sequence
from teleost ﬁsh to humans suggests a critical role for this nu-
clear receptor in numerous species. Nuclear receptors are tran-
scriptional factors that are involved in several diverse
physiological functions that include reproduction, development
and metabolism [3]. The human genome contains 48 nuclear
receptors. Most of these nuclear receptors have a poorly-de-
ﬁned N-terminal activation function domain 1 (AF1), a highly
conserved DNA binding domain (DBD), a hinge region that
links the DBD to a ligand-binding domain (LBD) that also con-
tains a strong transcriptional activation function domain 2
(AF2). In general, nuclear receptors bind as monomers or
dimers to speciﬁc DNA sequences termed hormone response
elements and regulate gene expression. Transcriptional activa-
tion is often stimulated when agonists (usually small lipophilic
molecules) bind to the pocket formed by the LBD, and alter the
conformation of the nuclear receptor; the result is often release
of co-repressors, recruitment of co-activators and activated
gene transcription [3,4]. Speciﬁc agonists include steroid
hormones, thyroid hormone, 1,25-dihydroxyvitamin D3, fatty
acids, oxysterols, retinoic acids, phospholipids and bile acids.
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processes that do not involve binding to DNA. The latter recep-
tors may either lack a DBD, or a ligand has yet to be identiﬁed
or they bind to and inhibit other transcription factors without
themselves interacting with DNA. Small heterodimer partner
(SHP; NR0B2) is but one example of a nuclear receptor that
lacks a DBD and represses gene transcription by binding to
and inhibiting other transcription factors [5].
FXRa expression is limited to very few tissues; it is highly
expressed in the liver, intestine, kidney and adrenal gland
[1,2,6,7]. In contrast, low FXR mRNA levels were detected
in white adipose tissue and heart [6,8,9]. Whether FXR is func-
tional and controls gene expression in vivo in the latter two tis-
sues remains to be determined. The single human or mouse
gene encodes four isoforms (FXRa1, FXRa2, FXRa3 and
FXRa4), as a result of the use of two diﬀerent promoters
and alternative splicing between exons 5 and 6 [6,7]. Compared
to FXRa1 and FXRa2, FXRa3 and FXRa4 mRNAs are
smaller but encode proteins that contain an extended N-termi-
nus. In addition, FXRa1 and FXRa3, but not FXRa2 and
FXRa4, contain a four amino acid (MYTG) insert immedi-
ately adjacent to the DBD. Although many genes are regulated
equally well in vitro by all four FXR isoforms, certain genes,
that include ileum bile acid-binding protein (I-BABP), syndec-
an-1, aA-crystallin and ﬁbroblast growth factor 19 (FGF19)
are more responsive to FXRa2 and FXRa4 (the isoforms that
lack the MYTG insert) (reviewed in [10]). Despite the identiﬁ-
cation of four FXR isoforms, the physiological importance of
gene regulation by each isoform remains to be established.
Rodents, rabbits and dogs contain a second Fxr gene, Fxrb
(NR1H5), that is a pseudogene in humans and primates. In
this review, we use the term FXR to refer speciﬁcally to FXRa.
FXR, like a subset of nuclear receptors, binds to speciﬁc
response elements as a heterodimer with retinoic X receptor
(RXR, NR2B1). The FXR response element (FXRE) contains
two copies of a consensus sequence (AGGTCA) arranged as
inverted repeats separated by one nucleotide (IR1) or everted
repeats separated by 8 nucleotides (ER8) or direct repeats
separated by four nucleotides (DR4) [11,12]. FXR has also
been reported to bind DNA as a monomer [13], although this
appears to be a rare event.
A number of excellent reviews on FXR and/or bile acid
metabolism have been published recently [10–12,14,15]. Conse-
quently, we propose here to emphasize the more recent ad-
vances that have delineated a role for FXR in bile acid,
lipoprotein and glucose metabolism, liver regeneration, bacte-
rial growth and tumor growth. Based on the many metabolicblished by Elsevier B.V. All rights reserved.
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speciﬁc agonists may prove useful in the treatment of cholesta-
sis, hyperlipidemia, diabetes and/or cholesterol gallstone dis-
ease.2. FXR agonists
In 1999 bile acids were identiﬁed as the endogenous ligands
that bind to and activate FXR [16–18]. The order of potency of
bile acids is chenodeoxycholic acid (CDCA) > lithocholic acid
(LCA) = deoxycholic acid (DCA) > cholic acid (CA). More
recently, androsterone was reported to function as an endo-
genous (although very weak) ligand for FXR [19].
However, it is now clear that bile acids are promiscuous acti-
vators of nuclear receptors since they not only activate FXR,
but also activate the pregnane X receptor (PXR), vitamin D
receptor (VDR) and the constitutive androstane receptor
(CAR) [10]. In addition, bile acids regulate c-Jun N-terminal
kinase (JNK) cascade and the mitogen-activated protein
kinase pathway, independent of nuclear receptor activation.
Finally, bile acids have recently been shown to activate
TGR5, a G-protein coupled receptor [20]. Thus, bile acids
can modulate numerous metabolic pathways by various mech-
anisms (reviewed in [10]).
The development of potent, speciﬁc FXR agonists, such as
GW4064 [21], fexaramine [22], AGN34 [23] and 6a-ethyl-che-
nodeoxycholic acid (6-ECDCA) [24], and the generation of
FXR-deﬁcient mice [25] have provided powerful tools to inves-
tigate the role of FXR in controlling diverse metabolic path-
ways. Because bile acids are promiscuous activators of many
pathways, such tools were particularly important in delineat-
ing FXR-dependent and -independent pathways.3. Regulation of FXR expression and activity
Little is known about the regulation of the FXR gene per se.
Hepatic FXR mRNA levels have been shown to be induced by
prolonged fasting [26]. Interestingly, peroxisome proliferator-
activated receptor c coactivator 1a (PGC-1a), which plays an
important role in glucose and energy homeostasis [27], is also
induced during the fast. FXR mRNA levels were also in-
creased following overexpression of PGC-1a in primary hepa-
tocytes [26]. This latter induction of FXR likely results from
PGC-1a coactivation of HNF4a bound to DR-1 elements in
the two FXR promoters [26]. In addition, PGC-1a may also
serve as a coactivator for FXR [26,28,29]. In other studies,
protein arginine methyl-transferase type I (PRMT1) [30],
TRRAP [31], and DRIP205 [32] have been identiﬁed as
FXR-interacting proteins that likely function as coactivators
of the nuclear receptor. Together, these data suggest that hepa-
tic FXR may be regulated by the nutritional status and might
be particularly responsive to the coactivator PGC-1a.
Recent studies have shown FXR mRNA levels are increased
in cultured cells in response to high levels of glucose [33]. This
stimulation may be of physiological importance since hepatic
FXR levels are elevated in diabetic db/db mice [34]. However,
Duran-Sandoval et al. have reported that hepatic FXR mRNA
levels are repressed in both streptozotocin (STZ)-induced dia-
betic rats and aging diabetic Zucker rats [33]. The reasons forthese apparent discrepancies remain unknown at the present
time.4. FXR and the regulation of bile acid metabolism
Bile acids, the end products of hepatic cholesterol catabo-
lism, are important for lipid digestion and absorption from
the intestinal lumen, serve as signaling molecules, and also rep-
resent the principal means of eliminating cholesterol from the
body. Importantly, in order to maintain whole body choles-
terol homeostasis, approximately 5% of the bile acids secreted
from the gall bladder into the duodenum fail to be reabsorbed
and are excreted in the feces.
4.1. FXR and bile acid synthesis
Cholesterol 7a-hydroxylase (CYP7A1) is the rate-limiting
enzyme in the classic pathway of bile acid synthesis [14]. It
has been known for many years that bile acids returning to
the liver via the enterohepatic circulation are capable of
repressing their own synthesis. The molecular mechanisms in-
volved in this repression appear to involve at least three path-
ways; SHP, mouse ﬁbroblast growth factor (FGF)15/human
FGF19 and JNK. Activation of hepatic FXR, in response to
bile acids returning to the liver after re-absorption from the
ileum, increases the expression of the FXR target gene SHP.
SHP in turn binds to and inactivates liver receptor homolog
1 (LRH-1, NR5A2), a transcription factor that is important
for Cyp7a1 expression. The result is SHP-dependent transcrip-
tional repression of Cyp7a1 [35,36]. Unexpectedly, hepatic
Cyp7a1 mRNA levels were repressed following treatment of
Shp/ mice with bile acids [37,38]. These latter data indicate
that other pathway(s), independent of SHP, are also involved
in the repression of Cyp7a1 by bile acids.
Recent studies have identiﬁed a second pathway that in-
volves FGF15; activation of intestinal FXR by GW4064 or
bile acids increases the expression and secretion of FGF15
from enterocytes. Secreted FGF15 subsequently binds to the
receptor FGFR4, localized on the plasma membrane of hepa-
tocytes, resulting in activation of the JNK pathway and repres-
sion of Cyp7a1 [39]. The ﬁnding that Fgfr4/ mice have
increased bile acid pools and increased Cyp7a1 expression is
entirely consistent with the critical role of Fgfr4 [40]. Bile acids
may also repress Cyp7a1 via direct activation of the JNK path-
way [41]. Together, these three pathways likely account for the
regulation of Cyp7a1 and the control of bile acid synthesis
from cholesterol.
4.2. FXR and bile acid conjugation, secretion and absorption
Once synthesized, bile acids are conjugated to taurine or gly-
cine prior to secretion across the canalicular membrane of the
hepatocytes. These reactions are catalyzed by bile acid-CoA
synthetase (BACS) and bile acid-CoA:amino acid N-acetyl-
transferase (BAT). FXR directly regulates both genes. In addi-
tion, FXR also regulates uridine 5 0-diphosphate glucurono-
syltransferase 2B4 (UGT2B4) and dehydroepiandrosterone-
sulfotransferase (STD; SULT2A1) (reviewed in [10]). UGT2B4
converts hydrophobic bile acids into more hydrophilic glucu-
ronide derivatives, whereas SULT2A1 is a hydroxysteroid
sulfo-conjugating enzyme. The up-regulation of BACS, BAT,
UGT2B4 and SULT2A1 suggests that FXR activation
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that precedes secretion.
Activated FXR also increases the transcription of three he-
patic transporters that function to eﬄux bile acids out of hepa-
tocytes (reviewed in [10,12]); the three proteins, bile salt export
protein (BSEP), the multidrug resistant-associated protein 2
(MRP2, ABCC2) and the multidrug resistance P-glycoprotein
3 (MDR3, ABCB4) are localized on the bile canalicular mem-
brane of hepatocytes and secrete bile acids (and other com-
pounds) from the hepatocytes into the bile canaliculi. Bile,
containing bile acids, phospholipids, cholesterol and some pro-
teins, is then stored in the gallbladder.
Entry of food into the intestine causes the release of chole-
cystokinin (CCK) from the proximal duodenum. CCK stimu-
lates the gall bladder to contract and expel bile into the
duodenum where it facilitates lipid digestion and absorption.
About 95% of the bile acids are re-absorbed in the distal ileum
via the apical sodium-dependent bile acid transporter (ASBT).
Ileum bile acid-binding protein (I-BABP) binds bile acids and
may protect the enterocytes from the eﬀects of high levels of
these detergents prior to their being pumped across the baso-
lateral membrane to the portal circulation via heterodimeric
organic solute transporter-a and -b (OSTa, OSTb). FXR has
been shown to directly regulate ASBT, IBABP and both
OST genes [10].
In a particularly insightful study, Kliewer and colleagues re-
cently demonstrated that the normal ﬁlling of the gall bladders
was dependent upon the FXR target gene FGF15 [42]. They
demonstrated that the reﬁlling of the gall bladder after
CCK-stimulated emptying is dependent upon the synthesis
and secretion of FGF15 from the distal ileum. Importantly,
these authors provided data to support a model in which bile
acids that are reabsorbed in the distal ileum, induce FGF15
expression by activating FXR in the enterocytes. The secreted
FGF15 subsequently binds to FGF15 receptors on the gall
bladder and promotes relaxation of gall bladder smooth mus-
cle to allow reﬁlling [42]. Since poor gall bladder motility has
been linked to gall stone formation, the authors suggest that
changes in FGF15 expression may prove clinically useful for
treatment of this disease that aﬄicts millions of people in the
USA [42].
Thus, it is clear that FXR is a key sensor for bile acids and
has a central role in maintaining bile acid homeostasis, as it
regulates all aspects of bile acid metabolism, including bile acid
synthesis, conjugation, secretion, absorption and reﬁlling of
the gall bladder.4.3. FXR and cholesterol gallstone disease
FXR has recently been shown to play a role in gallstone for-
mation. By using quantitative trait locus analysis, Wittenburg
et al. proposed that FXR and ABCG5/ABCG8 are possible
determinants of cholesterol gallstone disease [43]. Subse-
quently, Moschetta et al. demonstrated that, compared to
wild-type mice, Fxr/ mice were more susceptible to choles-
terol gallstone formation following administration of a litho-
genic diet [44]. Importantly, gallstone formation was reduced
when gallstone-susceptible C57L mice were treated with the
FXR agonist GW4064 [44]. The authors proposed that this
protection likely resulted from induction of Bsep and Mdr2
and increased transport of bile acids from the liver into bile.
Such increased levels of bile acids would be expected to preventor reduce cholesterol crystallization from the bile [44]. These
studies open up the possibility that FXR agonists may prove
useful in the treatment of cholesterol gallstone disease.5. FXR and lipid metabolism
It has been known for many years that the bile acid pool size
has a profound eﬀect on lipid metabolism [45–47]. The reduced
bile acid pool, following either administration of bile acid-
binding resins (e.g. cholestyramine or cholestipol) or ileal sur-
gery, results in reduced levels of plasma LDL and increased
plasma triglyceride and HDL. The ﬁnding that administration
of bile acids (CDCA or CA) to humans or animals results in
reduced plasma triglyceride and HDL levels and increased
LDL is entirely consistent with a key role for bile acids in con-
trolling plasma lipids (reviewed in [48]). Studies with Fxr/
mice or following administration of FXR-speciﬁc agonists
have demonstrated that FXR plays a central role in controlling
lipid homeostasis.
5.1. FXR and triglyceride metabolism
Recent data have demonstrated that activation of FXR re-
duces both hepatic lipogenesis and plasma triglyceride and
cholesterol levels. As detailed below, FXR activation induces
genes involved in lipoprotein metabolism/clearance and re-
presses hepatic genes involved in the synthesis of triglycerides
(Fig. 1). For example, treatment of mice with FXR agonists
results in the repression of Srebp-1c mRNA levels in murine
livers or isolated murine primary hepatocytes [26,49]. This
repression was not observed with Shp/ mice, suggesting that
SHP, a known FXR target gene, is required for the repression
[49]. Since SREBP-1c functions as a critical transcription fac-
tor that regulates many genes involved in both fatty acid and
triglyceride synthesis, it is not surprising that hepatic triglycer-
ide synthesis and secretion is reduced following the repression
of Srebp-1c by FXR. However, the ﬁnding that Fxr/ mice
have normal or even reduced hepatic SREBP-1c expression
[26,50] suggests that FXR-independent mechanisms must also
be important.
Activation of FXR also results in increased hepatic expres-
sion of receptors (VLDL receptor and syndecan-1) that are
involved in lipoprotein clearance and increased apoC-II that
co-activates lipoprotein lipase (LPL). In addition FXR activa-
tion results in decreased expression of proteins (apoC-III and
ANGTPL3) (reviewed in [10]) that normally function as inhib-
itors of LPL. Finally, FXR induces human PPARa [51], a
nuclear receptor that functions to promote fatty acid b-oxida-
tion. Taken together, these data suggest that FXR activation
lowers plasma triglyceride levels via both repressing hepatic
lipogenesis and triglyceride secretion, and increasing the clear-
ance of triglyceride-rich lipoproteins from the blood (Fig. 1).5.2. FXR and cholesterol metabolism
Treatment of mice with a speciﬁc FXR agonist results in a
decline in both plasma triglyceride and cholesterol. The obser-
vation that Fxr/ mice have increased plasma LDL and HDL
levels is consistent with an important role for FXR in control-
ling plasma lipoprotein levels [25,52]. The ﬁnding that Fxr/
mice have reduced hepatic expression of scavenger receptor,
type I B1 (SR-BI) [52], a receptor that is thought to be impor-
Fig. 1. Regulation of lipid homeostasis by hepatic FXR. Activation of hepatic FXR lowers plasma free fatty acid (FFA) and triglyceride (TG), likely
resulting from (i) repression of hepatic TG and fatty acid (FA) synthesis as a result of SHP-dependent inhibition of SREBP-1c; (ii) induction of
apoC-II and repression of apoC-III and ANGTPL3 in the liver, resulting in enhanced lipoprotein lipase (LPL) activity; (iii) induction of VLDL
receptor (VLDLR) and human syndecan-1 (hSyndecan-1), thus promoting clearance of TG-rich lipoproteins; and (iv) induction of human PPARa
and FA b-oxidation. In addition, FXR activation lowers plasma HDL cholesterol levels likely through the induction of hepatic SR-BI and increased
clearance of HDL. FXR-induced or -repressed genes are shown in green or yellow, respectively. The mechanisms of repression remain largely
unknown.
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the reverse cholesterol transport pathway, suggests that this
pathway may be impaired in Fxr/ mice. In agreement with
this observation, FXR activation was reported to induce hepa-
tic SR-BI expression [34]. Thus SR-BI may play a role in FXR-
controlled cholesterol homeostasis (Fig. 1).
5.3. FXR and atherosclerosis
The original observation that Fxr/ mice have a pro-ather-
genic lipoprotein proﬁle (increased plasma triglyceride, free
fatty acids and LDL) [25] suggested that these mice may have
altered susceptibility to atherogenesis. However, Fxr/ mice
on a chow or western diet fail to develop atherosclerotic lesions
(our unpublished data). To better assess the possible role of
FXR in atherogenesis, double knockout mice, either Fxr/
apoE/ [53,54] or Fxr/Ldlr/ [55], were generated and
fed a western diet. Surprisingly, compared to Ldlr/ mice,
male Fxr/Ldlr/ mice had decreased aortic atherosclerotic
lesions [55]. The decrease may be a result of decreased LDL
levels in the double knockout mice [55]. The mechanism result-
ing in this reduction in LDL remains unknown. Guo et al. also
observed decreased lesions in Fxr/apoE/ mice compared
to the apoE/ control mice [54]. Thus, loss of FXR unexpect-
edly resulted in reduced levels of atherosclerosis in two diﬀer-
ent double knockout mouse models of atherosclerosis.
However, in a third independent investigation, Hanniman
et al. reported that administration of a western diet to Fxr/
apoE/ mice resulted in increased atherosclerotic lesions as
compared to apoE/ control mice [53]. At present, the diﬀer-
ent results reported in the latter two studies with Fxr/apoE/
 mice remain unexplained.
Using a diﬀerent approach, Bishop-Bailey et al. used immu-
nohistochemistry and concluded that FXR is expressed in ath-
erosclerotic lesions and vascular smooth muscle cells of human
vessels [56]. In contrast, we have failed to identify FXR tran-scripts in macrophages or extracts from murine aortas (our
unpublished data). In addition, the level of FXR in human
umbilical vein endothelial cells (HUVEC) and human aortic
endothelial cells (HOVEC) was reported to be approximately
1/1000 of that in HepG2 cells [57]. Consequently it remains
to be established whether such low levels of FXR are suﬃcient
to regulate expression of known FXR target genes. The ﬁnding
that CDCA treatment caused reduced expression of endothe-
lin-1 [58], a vasoconstrictive peptide, and increased expression
of the adhesion molecules ICAM-1 and VCAM-1 [57] is of
interest. However, it remains possible that such regulation
may involve bile acid-regulated but FXR-independent path-
ways.6. FXR and glucose metabolism
Recent studies demonstrated that FXR also plays a signiﬁ-
cant role in regulating glucose homeostasis. Treatment of mice
with the FXR agonist GW4064 or cholic acid, or following
infection with adenovirus that expresses a constitutively active
FXR-VP16 fusion protein, resulted in a signiﬁcant reduction
of plasma glucose levels and improved insulin sensitivity
[8,34,59]. These eﬀects were noted in three diﬀerent diabetic
models (db/db, ob/ob or KK-A(y) mice). The ﬁnding that
over-expression of constitutively active FXR in the liver, as a
result of adenoviral infection, is consistent with a key role
for hepatic, rather than extra-hepatic FXR. As detailed below,
activation of hepatic FXR regulates gluconeogenesis, glycogen
synthesis and insulin sensitivity (Fig. 2).
6.1. FXR and hepatic gluconeogenesis
Hepatic gluconeogenesis plays an important role in main-
taining glucose homeostasis. The ﬁnding that plasma glucose
levels of db/db mice declined approximately 50% after hepatic
Fig. 2. Regulation of glucose homeostasis by activated FXR. Activation of hepatic FXR results in repression of PEPCK and G6Pase and increased
phosphorylation of GSK3b. Since phosphorylated GSK3b is inactive, the result is increased levels of the dephosphorylated/active glycogen synthase
(GS). Glucose 6 phosphate (G-6-P) also activates GS. Overall, these changes result in decreased hepatic gluconeogenesis, decreased plasma glucose
levels and increased hepatic glycogen synthesis. FXR activation also results in increased phosphorylation of hepatic IRS-1 and IRS-2 and increased
insulin sensitivity/signaling. It is currently not known whether the increased insulin sensitivity in the liver and muscle is a result of the reduction in the
plasma levels of free fatty acids (FFA) that occur as a result of inhibition of SREBP-1c (see also Fig. 1). Fxr/ mice display insulin resistance and
changes in muscle lipid levels and insulin signaling. Whether these changes in Fxr/ mice are a result of increased plasma FFAs is unknown at this
time. PEP, phosphoenoylpyruvate. F-6-P, fructose-6-phosphate.
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role for hepatic FXR. A similar decline in plasma glucose and
free fatty acids was noted following administration of GW4064
to db/db or KK-A(y) mice [34]. Plasma glucose levels also de-
clined following treatment of wild-type mice with GW4064 [34]
or bile acids [59]. The latter treatments are known to activate
intestinal, hepatic and renal FXR and thus do not identify
the tissue(s) responsible for the hypoglycemic eﬀect. The ﬁnd-
ing that activation of FXR repressed hepatic phosphoenoyl-
pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase
(G6Pase) mRNA levels [34,59] is consistent with the hypogly-
cemic eﬀects. It is possible that the repression of PEPCK and
G6Pase following FXR activation in diabetic mice results, at
least in part, from increased hepatic insulin sensitivity and re-
duced plasma free fatty acid levels [34]. There is also evidence
to suggest that cholic acid administered in the diet reduces he-
patic gluconeogenic genes through an FXR/SHP pathway [59].
In contrast to studies with diabetic mice, treatment of wild-
type mice with FXR agonists has resulted in inconsistent re-
sults (stimulation [34,60] or repression of PEPCK [59,61,62],
decreased or unchanged glucose levels [34,59,60]). The reason
for these discrepancies remains to be determined, but might de-
pend on eﬃcacy of treatment or genetic backgrounds of the
mice.
6.2. FXR and hepatic glycogen synthesis
The decreased hepatic expression of G6Pase following FXR
activation suggested that hepatic glycogen synthesis might be
altered. Consistent with this proposal, activation of FXR in
either murine primary hepatocytes or the livers of diabeticdb/db mice resulted in increased conversion of D-glucose to
glycogen or increased hepatic glycogen levels [34]. These
changes were associated with increased phosphorylation of
GSK3b [34], a known key regulator of glycogen synthase.
Not surprisingly, Fxr/ mice have reduced hepatic glycogen
content [63]. Currently, it is not known whether long term
FXR activation (>two weeks) would be deleterious as a result
of increased glycogen storage.
6.3. FXR and insulin sensitivity
Fxr/ mice show impaired glucose tolerance and insulin
sensitivity compared to wild-type mice [8,34,59]. Hyperinsuli-
nemic-euglycemic clamp studies reveal that Fxr/ mice also
display a peripheral insulin resistance [8,59]. Consistent with
this observation, insulin signaling was found to be impaired
in the liver [59], muscle [8,59] and white adipose tissue of
Fxr/ mice [8]. Such changes may result from the elevated free
fatty acids noted in the plasma of Fxr/ mice. Importantly,
glucose tolerance and insulin sensitivity were signiﬁcantly im-
proved when db/db [34] or ob/ob [8] mice were either treated
with GW4064 or infected with adenovirus expressing FXR-
VP16. The ﬁnding that activation of FXR signiﬁcantly lowered
plasma glucose, triglyceride, cholesterol and free fatty acid lev-
els in diabetic mouse models [34], suggests that FXR agonists
might prove useful in the treatment of hyperglycemia and
hyperlipidemia that are observed in patients with type 2 diabe-
tes.
Recently, FXR activation was reported to improve insulin
signaling and insulin-stimulated glucose uptake in diﬀerenti-
ated 3T3-L1 cells [8]. However, FXR is expressed at a very
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been identiﬁed in this tissue to date. Thus the physiological
importance of FXR in the direct regulation of insulin sensitiv-
ity in white adipose tissue awaits additional studies.7. FXR and intestinal bacterial growth
Obstruction of bile ﬂow in humans or rodents causes intes-
tinal bacterial growth, mucosal injury and bacterial transloca-
tion. In contrast, bile acid administration can prevent
intestinal bacterial growth and translocation [64,65]. Recently,
Inagaki et al. reported that FXR plays a critical role in these
processes [66]. They demonstrated that FXR activation in-
duced a number of intestinal genes, including angiogenin,
inducible nitric oxide synthase and IL-18, all of which are in-
volved in enteroprotection [66]. The ﬁnding that Fxr/ mice
have bacterial overgrowth in their ileum and a compromised
epithelial barrier [66] is entirely consistent with the proposal
that FXR is critical for controlling intestinal bacterial growth
and maintaining a competent barrier. These novel studies sug-
gest that the development of FXR agonists could provide a no-
vel mechanism for controlling intestinal bacterial growth.8. FXR and liver regeneration
Rodent liver has a remarkable ability to regenerate following
partial hepatectomy/damage. Huang et al. recently concluded
that bile acids have a novel role in this process; they reported
that a diet containing 0.2% cholic acid stimulated liver regen-
eration in partially hepatectomized mice, while diets contain-
ing the bile acid sequestrant cholestyramine impaired liver
regeneration [67]. Such sequestrants bind bile acids in the intes-
tinal lumen and increase their excretion to the feces by prevent-
ing their reabsorption from the intestinal lumen. Consistent
with these data, Fxr/ mice had impaired liver regeneration
ability [67]. Bile acids were shown to be required for the induc-
tion of the proliferation factor FoxM1b [67]. However, since
bile acids can activate both FXR-dependent and -independent
pathways, it remains to be established whether a speciﬁc FXR
agonist, such as GW4064, will have a similar role in liver
regeneration.9. FXR and liver tumorigenesis
Recently, FXR was reported to play a role in tumor growth.
At 12 months of age, both male and female Fxr/ mice
showed a high incidence of liver tumors, including hepatocel-
lular adenoma, carcinoma and hepatocholangiocellular carci-
noma [68,69]. These Fxr/ mice also exhibit elevated
expression of genes involved in inﬂammation and cell cycle
and elevated plasma bile acid levels [68,69]. Consistent with
these observations, administration of a diet supplemented with
0.2% cholic acid diet promoted N-nitrosodiethylamine-initi-
ated liver tumorigenesis, whereas feeding a diet containing
the bile acid sequestrant cholestyramine to lower the bile acid
pool size in the Fxr/ mice, signiﬁcantly reduced the incidence
of liver tumorigenesis [69]. Together, these observations sug-
gest a link between bile acid homeostasis, FXR and hepatic
tumorigenesis.10. FXR and cholestasis
To date, mutations or polymorphisms in FXR have not been
directly linked to any human disease. However, a number of
FXR target genes have been implicated in several inherited
cholestatic liver disorders.
FIC1 (ATP8B1) is a P-type ATPase and functions as an
aminophospholipid ﬂippase. Mutations in the FIC1 gene cause
both progressive familial intrahepatic cholestasis type 1 (PFIC-
1) and benign recurrent intrahepatic cholestasis type 1 (BRIC-
1) depending on the mutation [70]. Recent studies have re-
ported that decreased FXR expression and activity is associ-
ated with FIC1 mutations [71,72], suggesting that FXR may
play an important role in the pathogenesis of PFIC-1. PFIC-
2 results from mutations in the FXR target gene BSEP [73],
and is phenotypically similar to PFIC-1. PFIC-3 results from
mutations in MDR3 [74,75], another FXR target gene [10],
and is characterized by high serum c-glutamyltranspeptidase
activity, absence of phosphatidylcholine in the bile, bile ductu-
lar proliferation and biliary ﬁbrosis.
FXR activation has provided beneﬁcial eﬀects on several
experimental cholestatic rodent models. Both GW4064 and
6-ECDCA are shown to protect hepatocytes from cholesta-
sis induced by a-naphthylisothiocyanate and estrogen
[76,77]. Both GW4064 and 6-ECDCA induce Bsep, Mrp2
and Mrd2, and reverse ductular proliferation and necrosis
[76,77]. Interestingly, a recent report shows that Fxr/ mice
are protected from obstructive cholestasis [78]. Together, these
studies suggest that changes in FXR expression and activ-
ity may aﬀect numerous genes that are associated with chole-
stasis.11. Conclusion
The utilization of both FXR agonists and Fxr/ mice have
demonstrated that FXR signaling modulates many metabolic
pathways. The current data suggest that FXR agonists may
be useful in the treatment of type 2 diabetes, hypertriglyceride-
mia, certain cholestasis and cholesterol gallstone disease. How-
ever, to our knowledge, no reports on the clinical use of
synthetic FXR agonists have been reported to date. The devel-
opment of novel full or partial FXR agonists, that are easily
absorbed after oral administration, may provide the appropri-
ate tools to determine whether FXR activation is beneﬁcial for
patients with speciﬁc metabolic disorders.
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